Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6

Chirality

Volumn 11, Issue 1, 1999, Pages 1-9

  Narimatsu, Shizuo ^a   Kato, Rika ^b   Horie, Toshiharu ^b   Ono, Satoshi ^c   Tsutsui, Michio ^c   Yabusaki, Yoshiyasu ^d   Ohmori, Shigeru ^e   Kitada, Mitsukazu ^e   Ichioka, Takao ^f   Shimada, Noriaki ^g   Kato, Ryuichi ^h   Ishikawa, Tsutomu ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Central Research Lab   (Japan)

^d SUMITOMO CHEMICAL CO LTD   (Japan)

^e CHIBA UNIVERSITY HOSPITAL   (Japan)

^f Health Insurance Naruto Hospital   (Japan)

^g Technoresearch Center   (Japan)

^h KEIO UNIVERSITY   (Japan)

Author keywords

Amino acid; Bunitrolol 4 hydroxylation; CYP2D6 valine; CYP2D6 methionine; Enantioselectivity

Indexed keywords

4 HYDROXYBUNITROLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNITROLOL; DEBRISOQUINE 4 HYDROXYLASE; DRUG METABOLITE; METHIONINE; UNCLASSIFIED DRUG; VALINE;

ARTICLE; CELL STRAIN HEPG2; ENANTIOMER; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL; MICHAELIS CONSTANT; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADRENERGIC BETA-ANTAGONISTS; AMINO ACIDS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; HUMANS; HYDROXYLATION; KINETICS; METHIONINE; MICROSOMES, LIVER; OXIDATION-REDUCTION; PROPANOLAMINES; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; VALINE;

EID: 0032928627     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1999)11:1<1::AID-CHIR1>3.0.CO;2-E     Document Type: Article

References (28)

1. Masubuchi Y, Kagimoto N, Narimatsu S, Fujita S, Suzuki T. Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes. Drug Metab Dispos 1993;21: 1012-1016.
2. Masubuchi Y, Yamamoto LA, Uesaka M, Fujita S, Narimatsu S, Suzuki T. Stereoselectivity and enantiomer/enantiomer interaction in propranolol metabolism in rat liver microsomes. Biochem Pharmacol 1993;46:1759-1765.
3. Narimatsu S, Tachibana M, Masubuchi Y, Imaoka S, Funae Y, Suzuki T. Cytochrome P450 isozymes involved in aromatic hydroxylation and side-chain N-desisopropylation of alprenolol in rat liver microsomes. Biol Pharm Bull 1995;18:1060-1065.
4. Suzuki T, Narimatsu S, Fujita S, Masubuchi Y, Umeda S. Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of Dark Agouti rats. Biochem Pharmacol 1991;42:2241-2244.
5. Suzuki T, Narimatsu S, Fujita S, Masubuchi Y, Umeda S, Imaoka S, Funae Y. Purification and characterization of a cytochrome P450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats. Drug Metab Dispos 1992;20:367-373.
6. Narimatsu S, Huang Y, Mizukami T, Masubuchi Y, Suzuki T. Development of a high-performance liquid chromatographic method for the analysis of enantiomer/enantiomer interaction in oxidative metabolism of bunitrolol in rat liver microsomes. Anal Biochem 1994;222:256-261.
7. Barrett AM, Cullum VA. The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol 1968;34:43-55.
8. Morris TH, Kaumann AJ. Different steric characteristics of β1- and β2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1984;327: 176-179.
9. Suzuki T, Rikihisa T. Studies on absorption, distribution, metabolism, and excretion of bunitrolol, a β-adrenergic blocking agent in rats and mice. Arzneim-Forsch/Drug Res 1979;29:1707-1715.
10. Narimatsu S, Mizukami T, Huang Y, Masubuchi Y, Suzuki T. In vitro metabolic interaction of bunitrolol enantiomers in rabbit liver microsomes. J Pharm Pharmacol 1996;48:1185-1189.
11. Narimatsu S, Masubuchi Y, Hosokawa S, Ohmori S, Kitada M, Suzuki T. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation. Biol Pharm Bull 1994;17:803-807.
12. Narimatsu S, Gotoh M, Masubuchi Y, Hone T, Ohmori S, Kitada M, Kageyama T, Asaoka K, Yamamoto I, Suzuki T. Stereoselectivity in bunitrolol 4-hydroxylation in liver microsomes from marmosets and Japanese monkeys. Biol Pharm Bull 1996;19:1429-1433.
13. Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-Salguero P, Buters JTM, Gelboin JV, Gonzalez FJ, Idle JR, Daly AK. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 1995;5:234-243.
14. Ellis SW, Rowland K, Harlow JR, Simula AP, Lennard MS, Woods HF, Tucker GT, Wolf CR Regio- and enantioselective metabolism of metoprolol by two human cDNA-derived CYP2D6 proteins. Br J Pharmacol 1994;112(Suppl):244P.
15. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sasaki T, Yabusaki Y, Funae Y. Multiple forms of human P450 expressed in Saccharomyces cerevisiae: Systematic characterization and comparison with those of the rat. Biochem Pharmacol 1996;51:1041-1050.
16. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442-446.
17. Aoyama T, Nagata K, Yamazoe Y, Kato R, Matsunaga E, Gelboin HV, Gonzalez FJ. Cytochrome b5 potentiation of cytochrome P-450 catalytic activity demonstrated by a vaccinia virus-mediated in situ reconstitution system. Proc Natl Acad Sci USA 1990;87:5425-5429.
18. Omura T, Sato R. Carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239: 2370-2378.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
20. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 1981;4:879-885.
21. Ono S, Tsutsui M, Gonzalez FJ, Satoh T, Masubuchi Y, Horie T, Suzuki T, Narimatsu S. Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogenetics 1995;5:97-102.
22. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYF2D6 gene, a related gene, and pseudogene. Am J Hum Genet 1989;45:889-904.
23. Ellis SW, Roland K, Achland MJ, Rekka E, Simula AP, Lennard MS, Wolf CR, Tucker GT. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochem J 1996;316:647-654.
24. Mautz DS, Nelson WL, Shen DD. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab Dispos 1994;23:513-517.
25. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992;267:83-90.
26. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J. Structure and function of cytochrome P450: a comparative analysis of three crystal structures. Structure 1995;3:41-62.
27. Cupp-Vickery JR, Poulos TL. Structure of cytochrome P450eryF involved in erythromycin biosynthesis. Struct Biol 1995;2:144-153.
28. de Groot MJ, Vermeulen NPE, Kramer JD, van Acker FAA, Donne-Op den Kelder GM. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102 and P450 108. Chem Res Toxicol 1996;9:1079-1091.